The "National eHealth Initiatives Advancing Global Precision Medicine Market, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
Precision medicine is transitioning toward wider acceptance, due to mounting payer pressures and regulatory changes that are shifting pharma businesses from prescriptive to more predictive and personalized models. Emergence of value-based reimbursement models and healthcare consumerism trends are helping move the treatment model from one-size-fits-all' to a stratified and outcome-based targeted therapeutics concept called precision medicine' (PM).
Companion diagnostics (CDx) and targeted therapeutics (TRx) are going beyond oncology and spreading more toward therapeutic areas such as infectious diseases, central nervous system (CNS), and cardiovascular diseases. Despite a relatively high success rate for PM R&D assets commercialization in recent years, considerable challenges exist around proving clinical utility and a regulatory and reimbursement framework, which is rigid, decentralized, and non-uniform.
Advances in omics technologies help in identifying molecular targets with the help of molecular insights generated by datasets about the disease pathogenesis. PM informatics is the key component of the PM ecosystem. PM-cognitive analytic platforms capable of leveraging genomic, clinical, financial, and lifestyle data, while delivering actionable clinical insights at the point of care, are gaining market traction. Big Data and Artificial Intelligence (AI) are the key enablers for utilizing the full potential of PM for building predictive models based on multi-omics data, given a big hurdle in the adoption of PM is lack of technology infrastructure.
Genomic sequencing has huge potential to support the COVID-19 outbreak exploration, especially in comprehending the re-emergence of potential COVID-19 outbreaks.
In terms of geographic outlook, although the specific focus on PM research started in the United States and the EU, countries such as Canada, China, Australia, Taiwan, South Korea, Singapore, and Japan have made significant advances in recent years in this area by way of significant investments to develop in-country research and scientific expertise to improve access. Considering the infrastructure requirements for utilizing omics in clinical practice, China and Japan are beating other leading countries in terms of both research initiatives and regulations and infrastructure development.
This research service analyzes the key building blocks for the precision medicine ecosystem to provide strategic imperatives and growth opportunities for key participants. The study captures both the global and regional flavors for PM market opportunity realization such as: market projections, drivers and restraints, country readiness index, and major government and commercial initiatives. The study also provides live case studies and innovative business models for leading companies in the PM space.
Key Issues Addressed
What does the PM ecosystem look like? Who are the key stakeholders and what are their roles?
What are the gaps in the PM ecosystem and how these can be filled by market partners?
How big is the PM market? What are the growth opportunities by major therapeutic areas, market segments, and technologies by 2025?
What are the major market drivers and restraints for the PM market?
Which are the countries that demonstrate the highest growth opportunities for PM? How are the regulatory and reimbursement landscape evolving across these countries?
What are the most promising business models emerging in the healthcare space to enable PM practice?
What are the winning and losing strategies that can be gleaned from existing market case studies and companies to watch?
How are companies monetizing these emerging models, services, and solutions?
What are the human and material resources required, and what is the most efficient way to procure these?
What are the market projections for specific services and solutions?
For more information about this report visit https://www.researchandmarkets.com/r/jfqbri
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005307/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900